Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving REGENXBIO Inc. and its officers or directors [1] Group 1: Company Developments - On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its investigational gene therapy RGX-111 for treating MPS I due to a case of neoplasm in a participant [3] - The FDA also placed a clinical hold on RGX-121 for MPS II, citing similarities in products and shared risks between the studies [3] - Following the announcement, REGENXBIO's stock price dropped by $2.40 per share, or 17.9%, closing at $11.01 per share on the same day [3] Group 2: Legal and Investigative Actions - Pomerantz LLP is actively seeking investors of REGENXBIO to contact them regarding the investigation into potential securities fraud [1] - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Oracle Corporation and its officers or directors, following significant stock price declines related to financial disclosures and debt financing efforts [1]. Group 1: Contract and Financial Developments - On September 10, 2025, Oracle announced a $300 billion, five-year cloud computing contract with OpenAI to supply computing power [3]. - On November 13, 2025, Oracle sought to raise an additional $38 billion in debt to fund its AI initiatives, which included financing two data centers for the Oracle-OpenAI agreement [3]. - Following the debt announcement, Oracle's stock price dropped by $9.42 per share, or 4.15%, closing at $217.57 on November 13, 2025 [3]. Group 2: Earnings Call and CapEx Disclosure - During a December 10, 2025 earnings call, Oracle's Executive Vice President disclosed an expected increase in fiscal 2026 capital expenditures (CapEx) by approximately $15 billion compared to previous forecasts [4]. - This announcement led to a significant decline in Oracle's stock price, which fell by $24.16 per share, or 10.83%, closing at $198.85 on December 11, 2025 [4].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Aquestive Therapeutics, Inc. and its officers and directors [1]. Group 1: Company Overview - Aquestive Therapeutics, Inc. is currently facing scrutiny regarding its New Drug Application (NDA) for Anaphylm, as the FDA has identified deficiencies that prevent further discussions on labeling and post-marketing commitments [3]. - Following the announcement of the FDA's findings, Aquestive's stock price experienced a significant decline, falling by $2.30 per share, or 37.04%, closing at $3.91 per share on January 9, 2026 [3]. Group 2: Legal Investigation - Pomerantz LLP, a prominent law firm specializing in corporate and securities class litigation, is leading the investigation into the claims against Aquestive [1][4]. - The firm has a long history of advocating for victims of securities fraud and has successfully recovered multimillion-dollar damages for class members [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving First Western Financial, Inc. and its officers or directors [1]. Financial Performance - On January 22, 2026, First Western reported fourth-quarter earnings for 2025 of $0.34 per share, which fell short of analyst expectations [3]. - Following the earnings report, First Western's stock price decreased by $2.40 per share, representing an 8.81% decline, closing at $24.83 per share on January 23, 2026 [3].

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of Celestica Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1] - On January 22, 2026, news from Digitimes indicated that Alphabet Inc.'s Google may shift assembly work for its tensor processing units to other suppliers, which could reduce Celestica's role in assembling Google's AI servers [3] - Following the news about Google's potential shift, Celestica's stock price dropped by $18.83 per share, or 6.08%, closing at $290.92 per share on January 22, 2026 [3]

Core Viewpoint - A class action lawsuit has been filed against F5, Inc. regarding allegations of securities fraud and unlawful business practices related to a significant security breach and its impact on the company's financial performance [2][4]. Group 1: Lawsuit Details - The class action lawsuit concerns whether F5 and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased F5 securities during the Class Period have until February 17, 2026, to request to be appointed as Lead Plaintiff [2]. Group 2: Security Breach Impact - On October 15, 2025, F5 disclosed a "long-term, persistent" breach affecting its BIG-IP product development and engineering management platforms, including the compromise of the BIG-IP source code [4]. - Following the breach announcement, F5's stock price fell by $47.82 per share, or 13.93%, closing at $295.35 per share on October 16, 2025 [4][6]. - On October 27, 2025, F5 reported fiscal year 2025 results that significantly missed market growth expectations for fiscal year 2026, attributing this to the security breach, which led to expected reductions in sales and renewals, elongated sales cycles, and increased remediation expenses [5]. - After the fiscal results announcement, F5's stock price dropped another $30.76 per share, or 10.31%, closing at $258.76 per share on October 28, 2025 [6].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices involving AppLovin Corporation and its officers or directors [1] Group 1: Investigation and Allegations - Pomerantz LLP is conducting an investigation on behalf of AppLovin investors regarding possible securities fraud [1] - A report by CapitalWatch on January 21, 2026, accused AppLovin of being an "asset sale haven for cross-border black money," which allegedly violates anti-money-laundering laws [3] - Following the allegations, AppLovin's stock price dropped by $32.96, or 5.83%, closing at $532.56 per share on January 21, 2026 [3] Group 2: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of over 85 years in fighting for victims of securities fraud and corporate misconduct [4]

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Endeavor Group Holdings, Inc. (“Endeavor” or the “Company”) (NYSE: EDR).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether Endeavor and cer ...

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Regenxbio and its officers or directors following a significant stock price drop due to FDA clinical holds on its gene therapies [1][2]. Group 1: Company Overview - Regenxbio Inc. is a biotechnology company focused on gene therapy, specifically for conditions such as MPS I (Hurler syndrome) and MPS II (Hunter syndrome) [2]. - The company’s stock price fell by $2.40, or 17.9%, closing at $11.01 per share on January 28, 2026, after the announcement of the FDA's clinical holds [2]. Group 2: Regulatory Developments - The FDA placed a clinical hold on Regenxbio's investigational gene therapy RGX-111 due to a case of neoplasm in a participant from its Phase I/II study [2]. - A similar clinical hold was also placed on RGX-121, citing shared risks between the two studies [2]. Group 3: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [3].

NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of T1 Energy Inc. ("T1" or the "Company") (NYSE: TE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether T1 and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On January 21, 2026, Culper Research p ...